Literature DB >> 26944468

Psychometric properties, validity, and reliability of the Temporal Experience of Pleasure Scale state version in an opioid-dependent sample.

Joshua B B Garfield1, Sue M Cotton2, Dan I Lubman3.   

Abstract

BACKGROUND: Individuals with substance dependence commonly experience anhedonia. Theories of anhedonia distinguish between anticipatory and consummatory reward deficits, with the Temporal Experience of Pleasure Scale (TEPS) the first self-report scale to separately measure these two constructs. Several psychometric studies have analysed the trait version of the TEPS, but the state version of the TEPS has not been previously validated.
METHODS: We examined the psychometric properties of the state version of the TEPS in 121 individuals with opiate dependence (81% Australian-born), to confirm its 2-factor structure and examine the internal consistency, convergent and divergent validity, test-retest reliability, and performance as a state measure.
RESULTS: Confirmation of the 2-factor solution required removal of two items and allowing correlation between residuals of three pairs of highly-similar items. The resulting consummatory and anticipatory scales correlated strongly with each other (r=.76), suggesting poor divergent validity between them. Nevertheless, the scale showed good internal consistency (Chronbach's α: anticipatory=.90; consummatory=.84; total=.92), convergent (TEPS total and Snaith-Hamilton Pleasure Scale r=-.76) and divergent validity (-.38<r<-.10 for measures of negative affect, anxiety, and alexithymia) with other psychological measures, and test-retest reliability. Changes in TEPS scores between baseline and 1-month follow-up correlated well with changes in scores on other state anhedonia and positive affect measures, suggesting that the TEPS state version functions well as a state measure.
CONCLUSION: In opioid-dependent participants, the TEPS state version appeared to have good validity as a measure of state anhedonia. However, evidence for its ability to distinguish between consummatory and anticipatory anhedonia was weak.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anhedonia; Opioid use disorder; Psychometrics; Reliability; Substance dependence; Validity

Mesh:

Year:  2016        PMID: 26944468     DOI: 10.1016/j.drugalcdep.2016.02.011

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  I feel good? Anhedonia might not mean "without pleasure" for people treated for opioid use disorder.

Authors:  Samuel W Stull; Jeremiah W Bertz; Leigh V Panlilio; William J Kowalczyk; Karran A Phillips; Landhing M Moran; Jia-Ling Lin; Massoud Vahabzadeh; Patrick H Finan; Kenzie L Preston; David H Epstein
Journal:  J Abnorm Psychol       Date:  2021-07

2.  Clinical and Preclinical Assessments of Anhedonia in Psychiatric Disorders.

Authors:  Shijing Wang; Francesco Leri; Sakina J Rizvi
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.

Authors:  Brian D Kiluk; Sarah W Yip; Elise E DeVito; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  Clin Psychol Sci       Date:  2019-09-23

4.  Factor Structure, Convergent, and Divergent Validity of the Prodromal Questionnaire-Negative Symptom Subscale.

Authors:  Katherine M Pierce; Seth D Maxwell; Thomas M Olino; Shanna Cooper; Lauren M Ellman
Journal:  Assessment       Date:  2020-01-19

5.  Virtual Reality Reward Training for Anhedonia: A Pilot Study.

Authors:  Kelly Chen; Nora Barnes-Horowitz; Michael Treanor; Michael Sun; Katherine S Young; Michelle G Craske
Journal:  Front Psychol       Date:  2021-01-07

6.  Factor structure and sex invariance of the temporal experience of pleasure scale (TEPS) in Chinese university students and clinical population.

Authors:  Shulin Fang; Xiaodan Huang; Panwen Zhang; Jiayue He; Xingwei Luo; Jianghua Zhang; Yan Xiong; Fusheng Luo; Xiaosheng Wang; Shuqiao Yao; Xiang Wang
Journal:  BMC Psychiatry       Date:  2021-07-28       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.